# Immuno-Oncology Program

> **NIH NIH P30** · DUKE UNIVERSITY · 2022 · $72,653

## Abstract

ABSTRACT – HEMATOLOGIC MALIGNANCIES AND CELLULAR THERAPIES PROGRAM 
 The Hematologic Malignancies and Cellular Therapies Program (HMCT) is a multidisciplinary clinical, basic 
and translational research effort whose theme is to facilitate research with the ultimate objective to improve 
outcomes for patients with hematological malignancies. The broad, long-term goals of HMCT are to build on and 
extend current knowledge in the field of hematopoietic stem cell transplantation, immunotherapy and 
hematological malignancies, and to develop novel strategies for improving therapeutic results in patients with 
hematological malignancies through a collaborative and integrated approach involving the basic, translational 
and clinical investigators of HMCT. 
 The HMCT has two focus areas related to our scientific aims and theme: 1) Understanding the interplay 
between hematopoietic/immune cells and their microenvironment with respect to immune activation and 
suppression; and 2) translating laboratory-based observations to clinical trials. Among the strengths of the 
program are the significant numbers of physician scientists working on fundamental problems in hematological 
malignancies and who are able to take the basic observations at the bench to the bedside through extensive 
collaborations with the clinical researchers. Specially, the scientific goals of the HMCT Program are: 1) To 
understand the role of the external environment and microenvironment in immune responses; 2) To elucidate 
the role of immune and stromal cells in anti-tumor responses and graft-vs.-host disease (GVHD); 3) To develop 
and execute investigator-initiated translational trials for hematologic malignancies - all with the goal to stimulate 
and facilitate intra- and inter-programmatic collaborations; 4) To further advance genomic signatures in 
hematological malignancies and evaluate the role of different signaling mechanisms and; 5) To train the next 
generation of MD, PhD, and M.D./Ph.D. students, postdoctoral, fellows, residents in the field of adult and 
pediatric hematopoietic stem cell transplantation, immunotherapy and hematological malignancies. 
 The Program includes 36 primary and 9 secondary members from 6 departments and two schools within 
Duke University. Total direct funding for program members is $17.2M, of which $4.4M is peer-reviewed, including 
$1.6M from the NCI. From 2014- 2018, program members published 457 papers in peer-reviewed journals, 21% 
were intra-programmatic and 28% were inter-programmatic collaborations. During the current grant period, the 
program enrolled 1,519 subjects to all trials, 923 to interventional trials, and 587 to treatment trials.

## Key facts

- **NIH application ID:** 10323314
- **Project number:** 5P30CA014236-48
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Nelson J. Chao
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $72,653
- **Award type:** 5
- **Project period:** 1997-01-01 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10323314

## Citation

> US National Institutes of Health, RePORTER application 10323314, Immuno-Oncology Program (5P30CA014236-48). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10323314. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*